Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Debt (2016 - 2026)

Cumberland Pharmaceuticals' Total Debt history spans 15 years, with the latest figure at $5.2 million for Q4 2025.

  • On a quarterly basis, Total Debt fell 65.69% to $5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 million, a 65.69% decrease, with the full-year FY2025 number at $5.2 million, down 65.69% from a year prior.
  • Total Debt hit $5.2 million in Q4 2025 for Cumberland Pharmaceuticals, roughly flat from $5.2 million in the prior quarter.
  • Over the last five years, Total Debt for CPIX hit a ceiling of $20.0 million in Q1 2022 and a floor of $5.2 million in Q1 2025.
  • Historically, Total Debt has averaged $13.6 million across 5 years, with a median of $15.0 million in 2021.
  • Biggest five-year swings in Total Debt: skyrocketed 35.71% in 2022 and later plummeted 67.43% in 2025.
  • Tracing CPIX's Total Debt over 5 years: stood at $15.0 million in 2021, then grew by 8.0% to $16.2 million in 2022, then decreased by 21.09% to $12.8 million in 2023, then rose by 19.49% to $15.3 million in 2024, then crashed by 65.69% to $5.2 million in 2025.
  • Business Quant data shows Total Debt for CPIX at $5.2 million in Q4 2025, $5.2 million in Q3 2025, and $5.2 million in Q2 2025.